adenine has been researched along with olaparib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Curtis, A; Rajan, S; Rueter, J; Shopland, L; Zhang, R | 1 |
| Alonso-Pérez, V; Bastida, JM; Benito, R; García, JL; García-Tuñón, I; Gruber, M; Hernández-Rivas, JM; Hernández-Sánchez, JM; Hernández-Sánchez, M; Herrero, AB; Martín-Izquierdo, M; Ordóñez, JL; Quijada-Álamo, M; Rodríguez-Vicente, AE; San Segundo, L; Ten Hacken, E; Wu, CJ; Yin, S | 1 |
2 other study(ies) available for adenine and olaparib
| Article | Year |
|---|---|
Additive and synergistic inhibition of mantle cell lymphoma cell growth by combining olaparib with ibrutinib.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Humans; Lymphoma, Mantle-Cell; Phthalazines; Piperazines; Piperidines; Pyrazoles; Pyrimidines; Tumor Cells, Cultured | 2018 |
CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition.
Topics: Adenine; Animals; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Line, Tumor; Chromosome Deletion; Chromosomes, Human, Pair 11; CRISPR-Cas Systems; Drug Synergism; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mutagenesis, Site-Directed; Mutation; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Proto-Oncogene Proteins c-bcr; Pyrazoles; Pyrimidines; Xenograft Model Antitumor Assays | 2020 |